2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Bioinformatics, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult
PAPER

5717 Melphalan conditioning dose and outcomes after autologous hematopoietic cell transplantation in AL amyloidosis

Haritha Gandicheruvu, MD, Nabeeha Noor2, Muhammad Shahzad Sarwar, N/A3, Muhammad Kashif Amin, MD, MSc, FACP4, Shah Rukh5, Jeries Kort, MD6, Mehdi Hamadani, MD7, Al-Ola Abdallah, MD8, Moazzam Shahzad, MD9, Joseph P McGuirk, DO10, Muhammad Umair Mushtaq, MD11
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

Melphalan dose is frequently attenuated in patients with AL amyloidosis undergoing autologous hematopoietic cell transplantation (auto-HCT) based on organ involvement and comorbidity burden. However, the comparative impact of dose reduction across the full clinical range and the relative contribution of patient factors to outcomes remain incompletely defined in contemporary registry data.

Methods:

We performed a retrospective registry-based analysis of patients with AL amyloidosis who underwent melphalan-conditioned auto-HCT between 2014 and 2018 using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) using P-5378 dataset. Patients were stratified by conditioning dose: MEL100 (n=48), MEL140 (n=125), MEL180 (n=64), and MEL200 (n=203). Primary endpoints were overall survival (OS), relapse, and disease-free survival (DFS). Multivariable Cox proportional hazards models were adjusted for Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) and Karnofsky performance status (KPS), with MEL200 as the reference group. A landmark analysis at 24 months was performed to evaluate early (0–24 months) and late (>24 months) dose effects separately.

Results:

A total of 440 patients were included. Baseline characteristics differed significantly by dose group. Median age was higher in the lower-dose cohorts (MEL100: 63.2 years; MEL140: 62.7 years; MEL180/MEL200: 59.6 years). Patients receiving MEL100 or MEL140 more frequently had KPS <90 (77.1% and 64.7% vs 46.2% for MEL200), HCT-CI ≥3 (77.1% and 40.0% vs 30.5%), cardiac involvement (62.5% and 60.0% vs 38.9%), multi-organ involvement (≥2 organs: 56.3% and 49.6% vs 41.9%), and were less often treated at high-volume centers (≥4 HCT/year: 18.8% and 33.6% vs 58.6%). Renal involvement (~70% across groups) and bortezomib-based induction (76–83%) were comparable. Male sex ranged from 48–59%. On multivariable analysis, MEL100 and MEL140 were independently associated with inferior OS (HR 2.54, 95% CI 1.05–6.14 and HR 2.41, 95% CI 1.17–4.93), higher relapse (HR 2.26 and 2.21), and inferior DFS (HR 2.13 and 2.21; all p≤0.04) compared with MEL200. MEL180 did not differ from MEL200 for any endpoint (all p>0.5). Landmark analysis at 24 months showed that elevated hazards for MEL100/MEL140 persisted in both the early (0–24 months) and late (>24 months) periods for relapse and DFS (all p<0.05). Three-year OS was 95.8% (MEL100), 95.2% (MEL140), 98.4% (MEL180), and 97.5% (MEL200) (log-rank p=0.002); corresponding three-year DFS rates were 93.6%, 91.9%, 96.8%, and 97.0%. KPS <90 remained independently associated with inferior outcomes across all endpoints and time windows (HR 1.76–2.40; all p<0.02), whereas HCT-CI was not significant in any model.

Conclusions:

MEL100 and MEL140 were independently associated with inferior OS, relapse, and DFS compared with MEL200, with dose effects evident in both early and late post-transplant periods. MEL180 achieved outcomes comparable to MEL200. KPS, rather than HCT-CI, was the dominant prognostic factor, supporting its preferential use for risk stratification in this population.

Haritha Gandicheruvu, MD: No relevant conflicts of interest to declare.